| Literature DB >> 27994762 |
Chia-Yi Cheng1, Chun-Ping Chang1, Tsai-Ling Yang Lauderdale1, Guann-Yi Yu1, Jinq-Chyi Lee1, Yi-Wun Jhang1, Chien-Huang Wu1, Yi-Yu Ke1, Amit A Sadani1, Ching-Fang Yeh1, I-Wen Huang1, Yi-Ping Kuo1, De-Jiun Tsai1, Teng-Kuang Yeh1, Chen-Tso Tseng1, Jen-Shin Song1, Yu-Wei Liu1, Lun K Tsou1, Kak-Shan Shia1.
Abstract
Series of N-substituted carbazole analogues bearing an indole ring were synthesized as anti-methicillin-resistant Staphylococcus aureus (MRSA) agents from a molecular hybridization approach. The representative compound 19 showed an MIC = 1 μg/mL against a panel of MRSA clinical isolates as it possessed comparable in vitro activities to that of vancomycin. Moreover, compound 19 also exhibited MIC = 1 μg/mL activities against a recent identified Z172 MRSA strain (vancomycin-intermediate and daptomycin-nonsusceptible phenotype) and the vancomycin-resistant Enterococcus faecalis (VRE) strain. In a mouse model with lethal infection of MRSA (4N216), a 75% survival rate was observed after a single dose of compound 19 was intravenously administered at 20 mg/kg. In light of their equipotent activities against different MRSA isolates and VRE strain, the data underscore the importance of designed hybrid series for the development of new N-substituted carbazoles as potential anti-MRSA agents.Entities:
Keywords: Methicillin-resistant Staphylococcus aureus; carbazole derivatives; molecular hybridization; resistant bacteria; vancomycin
Year: 2016 PMID: 27994762 PMCID: PMC5151138 DOI: 10.1021/acsmedchemlett.6b00289
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345